RECRO PHARMA INC (REPH) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:REPH

2.09
-0.01 (-0.48%)
At close: Mar 21, 2022
2.09
0 (0%)
After Hours: 3/21/2022, 8:00:01 PM
Fundamental Rating

1

Taking everything into account, REPH scores 1 out of 10 in our fundamental rating. REPH was compared to 191 industry peers in the Pharmaceuticals industry. REPH may be in some trouble as it scores bad on both profitability and health. REPH is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • REPH had negative earnings in the past year.
REPH Yearly Net Income VS EBIT VS OCF VS FCFREPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 0 20M -20M -40M -60M

1.2 Ratios

Industry RankSector Rank
ROA -7.09%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
REPH Yearly ROA, ROE, ROICREPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 0 100 -100 200 300 400

1.3 Margins

Industry RankSector Rank
OM 0.55%
PM (TTM) -15.09%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
REPH Yearly Profit, Operating, Gross MarginsREPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 0 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, REPH has more shares outstanding
  • Compared to 1 year ago, REPH has an improved debt to assets ratio.
REPH Yearly Shares OutstandingREPH Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 10M 20M 30M 40M
REPH Yearly Total Debt VS Total AssetsREPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 50M 100M 150M

2.2 Solvency

  • REPH has an Altman-Z score of -0.81. This is a bad value and indicates that REPH is not financially healthy and even has some risk of bankruptcy.
  • A Debt/Equity ratio of 2.27 is on the high side and indicates that REPH has dependencies on debt financing.
Industry RankSector Rank
Debt/Equity 2.27
Debt/FCF N/A
Altman-Z -0.81
ROIC/WACCN/A
WACCN/A
REPH Yearly LT Debt VS Equity VS FCFREPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 0 50M -50M 100M

2.3 Liquidity

  • A Current Ratio of 3.24 indicates that REPH has no problem at all paying its short term obligations.
  • A Quick Ratio of 2.74 indicates that REPH has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 3.24
Quick Ratio 2.74
REPH Yearly Current Assets VS Current LiabilitesREPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • REPH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 73.04%, which is quite impressive.
  • Looking at the last year, REPH shows a quite strong growth in Revenue. The Revenue has grown by 13.32% in the last year.
  • The Revenue has been growing slightly by 1.68% on average over the past years.
EPS 1Y (TTM)73.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.67%
Revenue 1Y (TTM)13.32%
Revenue growth 3Y-0.87%
Revenue growth 5Y1.68%
Sales Q2Q%125.06%

3.2 Future

  • The Earnings Per Share is expected to grow by 1.18% on average over the next years.
  • REPH is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 15.49% yearly.
EPS Next Y5.68%
EPS Next 2Y10.01%
EPS Next 3Y4.51%
EPS Next 5Y1.18%
Revenue Next Year22.76%
Revenue Next 2Y15.97%
Revenue Next 3Y15.26%
Revenue Next 5Y15.49%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
REPH Yearly Revenue VS EstimatesREPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
REPH Yearly EPS VS EstimatesREPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1 -2

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for REPH. In the last year negative earnings were reported.
  • Also next year REPH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
REPH Price Earnings VS Forward Price EarningsREPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 21.28
REPH Per share dataREPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.01%
EPS Next 3Y4.51%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • REPH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

RECRO PHARMA INC

NASDAQ:REPH (3/21/2022, 8:00:01 PM)

After market: 2.09 0 (0%)

2.09

-0.01 (-0.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-01
Earnings (Next)05-04
Inst Owners1.05%
Inst Owner Change0%
Ins Owners17.64%
Ins Owner Change0%
Market Cap97.56M
Revenue(TTM)75.36M
Net Income(TTM)-11.37M
Analysts86.67
Price Target5.1 (144.02%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.29
P/FCF N/A
P/OCF N/A
P/B 2.32
P/tB N/A
EV/EBITDA 21.28
EPS(TTM)-0.31
EYN/A
EPS(NY)-0.29
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS1.61
BVpS0.9
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -7.09%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM 0.55%
PM (TTM) -15.09%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 2.27
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.24
Quick Ratio 2.74
Altman-Z -0.81
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)73.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.67%
EPS Next Y5.68%
EPS Next 2Y10.01%
EPS Next 3Y4.51%
EPS Next 5Y1.18%
Revenue 1Y (TTM)13.32%
Revenue growth 3Y-0.87%
Revenue growth 5Y1.68%
Sales Q2Q%125.06%
Revenue Next Year22.76%
Revenue Next 2Y15.97%
Revenue Next 3Y15.26%
Revenue Next 5Y15.49%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

RECRO PHARMA INC / REPH FAQ

What is the fundamental rating for REPH stock?

ChartMill assigns a fundamental rating of 4 / 10 to REPH.


What is the valuation status of RECRO PHARMA INC (REPH) stock?

ChartMill assigns a valuation rating of 1 / 10 to RECRO PHARMA INC (REPH). This can be considered as Overvalued.


Can you provide the profitability details for RECRO PHARMA INC?

RECRO PHARMA INC (REPH) has a profitability rating of 4 / 10.


What is the financial health of RECRO PHARMA INC (REPH) stock?

The financial health rating of RECRO PHARMA INC (REPH) is 3 / 10.